Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Cara Therapeutics Company Profile (NASDAQ:CARA)

Consensus Ratings for Cara Therapeutics (NASDAQ:CARA) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.00 (165.39% upside)

Analysts' Ratings History for Cara Therapeutics (NASDAQ:CARA)
Show:
DateFirmActionRatingPrice TargetDetailsShare
5/15/2014Canaccord GenuityBoost Price Target$25.00 -> $29.00ViewTweet This Rating  Share This Rating on StockTwits
2/27/2014Needham & Company LLCInitiated CoverageBuy$27.00ViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Stifel NicolausInitiated CoverageBuy$21.00ViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Canaccord GenuityInitiated CoverageBuy -> Buy$25.00ViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Janney Montgomery ScottInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Piper JaffrayInitiated CoverageOverweight$23.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 11/27/2012 forward)